Topic:

M&A

Latest Headlines

Latest Headlines

Will AbbVie now emerge as the next megamerger target?

Now that AbbVie has hammered out its $55 billion takeover deal for Shire, analysts are looking for the next big biopharma tax inversion deal.

Pharma peer pressure makes tax-friendly M&A targets the new must-have

Talk about peer pressure. First, a couple of U.S. drugmakers pull off trans-Atlantic deals that shift their official HQs and lower their tax rates. Next, some bigger names go for the same tax-inversion strategy. Now, investors want to know why every drugmaker isn't jumping in.

Roche CEO: No appetite for expensive megadeals here

Not every drug chief wants to ride the wave of M&A sweeping through pharma. Example: Roche CEO Severin Schwan, who says he'll stay in the shallows.

CRO Chiltern snags rival Ockham to bolster its oncology footprint

Chiltern has acquired Ockham, a fellow contract researcher, planning to absorb the company's capabilities and expand its service offerings.

Valeant wants Allergan shareholders to see growth at Bausch & Lomb

Valeant, which is trying to overcome resistance from the management of Allergan for its $53 billion buyout offer, has filed a new presentation with the SEC in preparation for an investor meeting.

AbbVie finally gets Shire, its low tax base and enough new drugs to protect its future

With a bid reaching nearly $55 billion and some goodies for the top execs, AbbVie was finally able to get Ireland-based Shire to surrender its independence, a portfolio of attention deficit hyperactivity disorder and rare disease drugs, and its low Irish tax base.

AbbVie and Shire come to terms on a $55B union

After months of semi-clandestine courtship, AbbVie and Shire have settled on a price: For $54.7 billion in cash and stock, the U.S. drugmaker will absorb its Irish target, securing a pipeline of promising rare disease treatments and a new address that should slash its tax rate.

Baxter International gets Q2 infusion from acquisition of Swiss dialysis outfit

Baxter International is riding high off promising second-quarter earnings, numbers that the company largely attributes to its 2013 acquisition of Swiss dialysis heavyweight Gambro.

Ackman to Allergan shareholders: Valeant's offer won't last forever

Valeant may be offering $53 billion for Allergan now. But that bid might not be on the table by the time 2015 rolls around, Bill Ackman, head of Valeant takeover partner Pershing Square Capital Management, told the Botox maker's shareholders on a webcast Thursday.

Danaher adds to its diagnostics biz, but deal may not be large enough for the Street

Once known as a serial acquirer, Danaher broke its big acquisition drought with the addition of Siemen's clinical microbiology unit to its Beckman Coulter division. The price was not disclosed, but company officials described it as the largest deal in two years during the quarterly earnings call on the heels of the July 17 announcement.